Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 25:11:1826.
doi: 10.3389/fimmu.2020.01826. eCollection 2020.

Predicting Success of Allergen-Specific Immunotherapy

Affiliations
Review

Predicting Success of Allergen-Specific Immunotherapy

Ulrich M Zissler et al. Front Immunol. .

Abstract

The immune response to antigens is a key aspect of immunology, as it provides opportunities for therapeutic intervention. However, the induction of immunological tolerance is an evolving area that is still not sufficiently understood. Allergen immunotherapy (AIT) is a disease-modulating therapy available for immunoglobulin E (IgE)-mediated airway diseases such as allergic rhinitis or allergic asthma. This disease-modifying effect is not only antigen driven but also antigen specific. The specificity and also the long-lasting, often life-long symptom reduction make the therapy attractive for patients. Additionally, the chance to prevent the onset of asthma by treating allergic rhinitis with AIT is important. The mechanism and, in consequence, therapy guiding biomarker are still in its infancy. Recent studies demonstrated that the interaction of T, B, dendritic, and epithelial cells and macrophages are individually contributing to clinical tolerance and therefore underline the need for a system to monitor the progress and success of AIT. As clinical improvement is often accompanied by decreases in numbers of effector cells in the tissue, analyses of cellular responses and cytokine pattern provide a good insight into the mechanisms of AIT. The suppression of type-2 immunity is accompanied by decreased levels of type-2 mediators such as epithelial CCL-26 and interleukin (IL)-4, IL-13 produced by T cells that are constituting the immune memory and are increasingly controlled by regulatory T and B cells following AIT. Immune tolerance is also associated with increased production of type-1 mediators like interferon-gamma, tissue-homeostating factors like indoleamine 2,3-dioxygenase (IDO) expressed by macrophages and dendritic cells. Although these individual genes were convincingly demonstrated to play a role immune tolerance, they do not predict therapy outcomes of AIT on an individual level. Therefore, combinations or ratios of gene expression levels are a promising way to achieve predictive value and definition of helpful biomarker.

Keywords: allergen-specific immunotherapy; asthma; biomarker; epithelial cells; immune cells; rhinitis; tissue homeostasis; tolerance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The scheme is illustrating distinct cellular mediators that have been shown to be involved in the immune regulation in allergen-specific immune tolerance. In green are shown genes that appear in the process of tolerance induction, in red are those that indicate a proallergic, inflammatory direction.

References

    1. Gutermuth J, Schmidt-Weber CB, Blank S. Supporting allergen-specific immunotherapy by inhibition of Janus kinases. Allergy. (2019) 74:1814–6. 10.1111/all.13808 - DOI - PubMed
    1. Jensen-Jarolim E, Bachmann MF, Bonini S, Jacobsen L, Jutel M, Klimek L, et al. . State-of-the-art in marketed adjuvants and formulations in allergen immunotherapy: a position paper of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. (2020) 75:746–60. 10.1111/all.14134 - DOI - PubMed
    1. Pfaar O, Agache I, de Blay F, Bonini S, Chaker AM, Durham SR, et al. . Perspectives in allergen immunotherapy: 2019 and beyond. Allergy. (2019) 74 (Suppl. 108):3–25. 10.1111/all.14077 - DOI - PubMed
    1. Pfaar O, Bonini S, Cardona V, Demoly P, Jakob T, Jutel M, et al. . Perspectives in allergen immunotherapy: 2017 and beyond. Allergy. (2018) 73 (Suppl. 104):5–23. 10.1111/all.13355 - DOI - PubMed
    1. Russkamp D, Aguilar-Pimentel A, Alessandrini F, Gailus-Durner V, Fuchs H, Ohnmacht C, et al. . IL-4 receptor alpha blockade prevents sensitization and alters acute and long-lasting effects of allergen-specific immunotherapy of murine allergic asthma. Allergy. (2019) 74:1549–60. 10.1111/all.13759 - DOI - PubMed

Publication types

LinkOut - more resources